Global Myocardial Infarction Market Analysis 2024, Forecast To 2033
8 Mar, 2024
The myocardial infarction market has witnessed robust growth, increasing from $1.9 billion in 2023 to $2.04 billion in 2024, with a CAGR of 7.7%. Growth drivers include the introduction of beta-blockers, chest pain centers, and personalized medicine approaches. Projections suggest further expansion, reaching $2.68 billion in 2028, with a CAGR of 7.1%. This growth is fueled by global health initiatives, reperfusion therapy access, and innovations in cardiac care, with trends focusing on cardiovascular imaging advancements and the integration of artificial intelligence.
Global Myocardial Infarction Market Key Driver
The growing number of smokers is projected to boost the myocardial infarction market. Smoking increases the risk of blood clot formation, leading to heart attacks. Data from the Office for National Statistics show an increase in smoking prevalence among the UK population aged 25 to 34, reaching approximately 16.3% in 2022. This trend underscores the role of smoking habits in driving the myocardial infarction market's growth.
Get A Free Sample Of The Global Myocardial Infarction Market ReportGlobal Myocardial Infarction Market Segments
The myocardial infarction market covered in this report is segmented –
1) Drug Class:Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics, Thrombolytics
2) Route Of Administration:Oral, Injectable
3) Distribution Channel:Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The countries covered in the myocardial infarction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the myocardial infarction market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Myocardial Infarction Industry Players
Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Bayer AG; Novartis AG; Sanofi SA; Bristol-Myers Squibb Company; AstraZeneca PLC; Abbott Laboratories; Boehringer Ingelheim GmbH; Merck KGaA; Daiichi Sankyo Co. Ltd.; Bio-Rad Laboratories Inc.; Apotex Inc.; Siemens Healthcare Diagnostics Limited; Annexin Pharmaceuticals AB; Dynavax Technologies Corp; Heartseed Inc.; Par Pharmaceutical Companies Inc.; Tenaya Therapeutics Inc.; Idorsia Pharmaceuticals Ltd.; Acesion Pharma ApS; Applied Therapeutics Inc.; Athersys Inc.; Cardurion Pharmaceuticals Inc.; Verve Therapeutics Inc.; Serca Pharmaceuticals AS
Get The Full Global Myocardial Infarction Market Report
Myocardial Infarction Market Overview
Myocardial infarction is a potentially fatal disorder that develops when the heart muscle's blood supply is suddenly interrupted, resulting in tissue damage. Myocardial infarction is triggered by high levels of low-density lipoprotein in the blood, high blood pressure, and smoking.